25.01.2014 Views

Pitfalls in Clinical Research

Pitfalls in Clinical Research

Pitfalls in Clinical Research

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

<strong>Pitfalls</strong> <strong>in</strong> Cl<strong>in</strong>ical <strong>Research</strong><br />

Piotr Zaborowski<br />

Medical University of Warsaw


Cl<strong>in</strong>ical research<br />

means not only<br />

„cl<strong>in</strong>ical trials”<br />

but also<br />

„cl<strong>in</strong>ical behaviour”


The most commonly reported reasons and<br />

justifications of conduct<strong>in</strong>g the research<br />

<strong>in</strong> cl<strong>in</strong>ical environment are:<br />

• patients’ benefit<br />

• improv<strong>in</strong>g the cl<strong>in</strong>ical practice<br />

• ga<strong>in</strong><strong>in</strong>g of experience and knowledge<br />

• progress <strong>in</strong> medic<strong>in</strong>e


On the background of these ideal world<br />

are:<br />

• high impact publications<br />

• popularity and glory<br />

• money<br />

• good relations


Pr<strong>in</strong>ciples of cl<strong>in</strong>ical research<br />

• The basic demand from any research is<br />

bee<strong>in</strong>g ethical. These <strong>in</strong>volves all steps and<br />

phases of the study<br />

• All ethical considerations should be<br />

„patient oriented” (patient benefit,<br />

translational rather than pr<strong>in</strong>ciple based<br />

ethics, valid consent).


Basic rules and basic pitfalls:<br />

1. respect<strong>in</strong>g patient’s rights<br />

2. avoid<strong>in</strong>g research misconduct<br />

- study design and end-po<strong>in</strong>ts<br />

- <strong>in</strong>clusion and exclusion criteria<br />

- randomisation<br />

- data analysis<br />

- publication of the results<br />

- sponsorship


1. PATIENTS’ RIGHTS<br />

• protection of personal autonomy<br />

• to be <strong>in</strong>formed<br />

• access to health care<br />

• appropriate quality of health care<br />

• free choice of caregiver


Pr<strong>in</strong>ciple-based ethics<br />

• beneficence,<br />

• non-maleficence,<br />

• respect for patient's autonomy, and<br />

• justice<br />

("Georgetown mantra")<br />

[Beauchamp RL,Childress JF: Encyclopedia of Bioethics,1995:215-20]


Translational ethics<br />

• autonomy of the patient and<br />

• <strong>in</strong>formed consent<br />

Kagarise MJ, Sheldon G: Arch Surg. 2000;135:39-45.


Autonomy<br />

• self determ<strong>in</strong>ation and<br />

• <strong>in</strong>dependence<br />

(autonomous choices [<strong>in</strong>formed consent,<br />

<strong>in</strong>formed refusal, <strong>in</strong>formed choice] – patient is<br />

expert about his own life and psychosocialspiritual<br />

circumstances; he contributes decision<br />

mak<strong>in</strong>g by express<strong>in</strong>g his personal preferences,<br />

beliefs and values i.e. “personal freedom” and<br />

“freedom of choice”)<br />

• right to privacy and confidentiality<br />

(regard<strong>in</strong>g all health problems)


Legal validity of <strong>in</strong>formed consent<br />

1. patients’ ability to give consent<br />

2. sufficient <strong>in</strong>formation<br />

3. appropriate form of consent


Has the patient also obligations?<br />

• “reasonable patient” standard<br />

• “competent partner – patient”<br />

• (social context of the patients’ rights)


2. Avoid<strong>in</strong>g research misconduct<br />

- study design and end-po<strong>in</strong>ts<br />

(open trials- observer bias; s<strong>in</strong>gle-, double bl<strong>in</strong>d; placebo<br />

controlled; „efficacy and safety”; equivalence and non<strong>in</strong>feriority<br />

trials; mortality, eg. <strong>in</strong>fant mortality as a function<br />

of birth weight disregard<strong>in</strong>g gestational age and fetal<br />

„growth”; costs, eg. cost of the procedure without cost of<br />

complications)<br />

- <strong>in</strong>clusion and exclusion criteria<br />

(pre-study dropouts, eg: exclusion of patients with no<br />

opportunity for follow-up visits; <strong>in</strong>clusion criteria <strong>in</strong>clud<strong>in</strong>g<br />

patients with better prognosis


2. Avoid<strong>in</strong>g research misconduct<br />

- randomisation<br />

(local vs central; cluster randomisation; Zelen’s<br />

prerandomisation design [eligibility, <strong>in</strong>formation, consent,<br />

randomisation] - facilitat<strong>in</strong>g patients’ entry but „mak<strong>in</strong>g”<br />

him defensible <strong>in</strong> the choice of treatment options)<br />

- data analysis<br />

(PP [per protocol], ITT [<strong>in</strong>tention-to-treat], NNT [number<br />

needed to treat])<br />

- publication of the results (researchers or sponsor)<br />

- sponsorship („who w<strong>in</strong>s the reward” - patients,<br />

researcher, „practice”, system, sponsor)

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!